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Background: Alpha-momorcharin (α-MMC) and momordica anti-HIV protein (MAP30) 
derived from Momordica charantia L. have been confirmed to possess antitumor and antivirus 
activities due to their RNA-N-glycosidase activity. However, strong immunogenicity and short 
plasma half-life limit their clinical application. To solve this problem, the two proteins were 
modified with (mPEG)
2
-Lys-NHS (20 kDa).
Methodology/principal findings: In this article, a novel purification strategy for the two main 
type I ribosome-inactivating proteins (RIPs), α-MMC and MAP30, was successfully developed 
for laboratory-scale preparation. Using this dramatic method, 200 mg of α-MMC and about 
120 mg of MAP30 was obtained in only one purification process from 200 g of Momordica 
charantia seeds. The homogeneity and some other properties of the two proteins were assessed 
by gradient SDS-PAGE, electrospray ionization quadruple mass spectrometry, and N-terminal 
sequence analysis as well as Western blot. Two polyethylene glycol (PEG)ylated proteins were 
synthesized and purified. Homogeneous mono-, di-, or tri-PEGylated proteins were characterized 
by matrix-assisted laser desorption ionization-time of flight mass spectrometry. The analysis of 
antitumor and antivirus activities indicated that the serial PEGylated RIPs preserved moderate 
activities on JAR choriocarcinoma cells and herpes simplex virus-1. Furthermore, both PEGy-
lated proteins showed about 60%–70% antitumor and antivirus activities, and at the same time 
decreased 50%–70% immunogenicity when compared with their unmodified counterparts.
Conclusion/significance: α-MMC and MAP30 obtained from this novel purification strategy 
can meet the requirement of a large amount of samples for research. Their chemical modification 
can solve the problem of strong immunogenicity and meanwhile preserve moderate activities. 
All these findings suggest the potential application of PEGylated α-MMC and PEGylated 
MAP30 as antitumor and antivirus agents. According to these results, PEGylated RIPs can be 
constructed with nanomaterials to be a targeting drug that can further decrease immunogenic-
ity and side effects. Through nanotechnology we can make them low-release drugs, which can 
further prolong their half-life period in the human body.
Keywords: ribosome-inactivating proteins, alpha-momorcharin, momordica anti-HIV protein, 
antitumor, antivirus, (mPEG)
2
-Lys-NHS (20 kDa), immunogenicity
Introduction
Momordica charantia L. (MC), a Momordica Linn. genus of the family Cucurbitaceae 
and commonly known as bitter melon, is a traditional medicine plant indigenous to 
China.1 The fruit and seed extracts from MC have been used in China for centuries 
for antivirus, antitumor, and immunopotentiating agent purposes.2 In recent years, 
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several ribosome-inactivating proteins (RIPs), including 
momordica anti-HIV protein (MAP30) and α-momorcharin 
(MMC), β-MMC, and γ-MMC, a group of which belong to 
the family of single-chain RIPs, were found to have the abil-
ity to inhibit protein biosynthesis in tumor cells by catalytic 
inactivation of the 60S ribosomal subunit.3,4 These proteins 
were also found to be able to inhibit the multiplication of 
herpes simplex virus-1 (HSV-1),4,5 poliovirus I in Hep2 cells,6 
and acquired human immunodeficiency virus type-l (HIV-l).7 
However, the strong immunogenicity, allergic reaction, and 
short half-life of these proteins have been considered the 
major barriers for their application as therapeutic agents in 
vivo.8,9 In recent years, researchers have shifted their focus 
to other technologies. An established technology, polyeth-
ylene glycol (PEG) conjugation (PEGylation), can bestow 
on proteins several benefits, such as increasing plasma 
half-life, decreasing toxicity, and reducing immunogenicity 
and antigenicity.9,10 The Food and Drug Administration has 
approved the PEGylated forms of the therapeutic proteins 
such as uricase, erythropoietin, granulocyte-colony stimulat-
ing factor, interferon, adenosine deaminase, asparaginase, 
and a growth hormone antagonist. Another technology is 
nanotechnology, which uses nanomaterials for packing 
potential therapeutic proteins to extend the half-life period 
or to make them targeting drugs.
α-MMC and MAP30 as potential therapeutic proteins 
possess biological activities such as inhibiting protein bio-
synthesis (ribosome inactivation),11 antitumor, antivirus, 
and, especially, anti-HIV replication.7,12,13 However, as 
foreign proteins are like other potential therapeutic proteins, 
poor biocompatibility limits their further development and 
application. To overcome these problems, in this study we 
first purified the two main proteins from bitter melon seeds 
and carried out their PEGylation using a branched 20 kDa 
(mPEG)
2
-Lys-NHS directed specifically to lysil ε-amino 
groups. Homogeneous one-mer, two-mer, and three-mer 
PEG-RIPs were then identified by matrix-assisted laser 
desorption ionization-time of flight mass spectrometry 
(MALDI-TOF-MS). Not only was their immunogenicity 
in vivo remarkably decreased but also, importantly, their 
antitumor and antivirus activities in vitro were moderately 
influenced when compared with the un-PEGylated coun-
terparts. This work is just the beginning step towards them 
being used clinically. The application of PEGylation and 
nanotechnolgy may indicate that the potential application of 
both α-MMC and MAP30 can be developed for antitumor 
and antivirus agents in the future.
Materials and methods
Materials
Bitter melon seeds were obtained from the Institute of 
 Agricultural Science and Technique of Sichuan Province, 
China. Matrices for electrophoresis were products of Sigma-
Aldrich (St Louis, MO) and Bio-Rad Laboratories (Hercules, 
CA). SP-Sepharose FF, Sephacryl S-100, Macro-Cap-SP, 
and ampholyte were purchased from Amersham Pharmacia 
Biotech (Piscataway, NJ). (mPEG)
2
-Lys-NHS (20 kDa) 
was obtained from Shearwater Polymers (Huntsville, AL). 
Dulbecco’s Modified Eagle’s Medium (DMEM) and fetal 
bovine serum used in cell culture were from Gibco BRL 
(Grand Island, NE). pUC18 DNA was purchased from 
TAKARA (Dalian, China). Nitrocellulose (NC) membrane 
was obtained from Bio-Rad Laboratories. Sheep-antimouse 
Ab-linked to alkaline phosphatase was purchased from 
Sigma-Aldrich. JAR choriocarcinoma cells were purchased 
from the Cell Bank of Shanghai Institute of Cell Biology 
(Shanghai, China).
Purification of α-MMC and MAP30
All steps tried either alone or in combination within the  process 
of purification were carried out at 4–6°C unless specifically 
stated. Firstly, the powder from fresh bitter melon seeds was 
extracted in 0.15 M NaCl solution and then the pH of the 
solution was adjusted to 4.0. After simple  centrifugation, the 
supernatant was neutralized and  fractionated by 30%–65% 
ammonium sulfate. The precipitate was dialyzed against the 
pH 6.3, 0.05 M phosphate buffer. Secondly, the sample was 
applied onto a SP-Sepharose FF column and eluted with 
pH 6.3, 0.05 M phosphate  buffer containing 0.15 M NaCl. 
The elution peak containing 30 kDa protein was collected. 
Thirdly, the portion was loaded onto a Sephacryl S-100 
 column and the elution peak with 30 kDa protein was pooled. 
Finally, the sample was applied onto a Macro-Cap-SP  column. 
A linear gradient of 0–0.15 M NaCl in pH 7.0, 20 mM sodium 
phosphate buffer eluted the  column and two peaks with 
30 kDa proteins were  respectively collected.
Determination of protein concentration
Protein concentration was determined by the method of 
Lowry et al14 or ultraviolet spectrometry at 280 nm using 
bovine serum albumin (BSA) as standard.
Identification of α-MMC and MAP30
SDS-PAgE
SDS-PAGE was performed according to Laemmli.15
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Assay of the amino-terminal sequence ESI-QUAD-MS 
and MALDI-TOF-MS
Both the amino-terminal sequences MALDI-TOF-MS 
and electrospray ionization quadruple mass spectrometry 
(ESI-QUAD-MS) were consigned to the Beijing Proteome 
Research Center of China to complete the analysis.
Western blotting analysis
Briefly, α-MMC was separated on SDS-PAGE and then 
transferred to an NC membrane. Nonspecific binding was 
blocked and washed by placing the membrane in a solu-
tion of BSA. NC  membrane was incubated with a mouse 
anti-α-MMC McAb and was exposed to a sheep-antimouse 
Ab linked to alkaline  phosphatase. After adding BCIP 
(5-bromo-4-chloro-3-indolyl phosphate), the colored 
bands were visualized and  photographed.16 In the analysis 
of MAP30, NC membrane was incubated with a diluted 
solution of rat anti-MAP30 PcAb under gentle agitation. 
Other conditions were the same with α-MMC.
Chemical synthesis and identification 
of PEgylated α-MMC and PEgylated 
MAP30
In general, PEGylated α-MMC and PEGylated MAP30 can 
be obtained in the following optimal conditions: 10 mg/mL 
of α-MMC or MAP30 reacted with (mPEG)
2
-Lys-NHS (mass 
ratio of PEG:RIP was 2:1) in pH 8.5,100 mM borate buffer 
at room temperature for 30 minutes. The reaction mixture 
was applied with Sephacryl S-100 column. The PEGylated 
conjugates can be collected and assessed by gradient SDS-
PAGE and MALDI-TOF-MS.
Topological inactivation activity
Topological inactivation activity was according to a previ-
ously described method.17
Antitumor activity in vitro
JAR choriocarcinoma cells were maintained in an incuba-
tor supplied with a humidified atmosphere of 5% CO
2
 at 
37°C. The culture medium was DMEM containing 20 mM 
HEPES and 10% fetal bovine serum. The cell viability 
and proliferation were determined by quantitative 3-(4,5-
dimethylthiozol-2-yl)-2,5- diphenyltetrazolium bromide 
(MTT). A total of 3 × 104 cells/mL were applied into 
96-well microtiter plates at 100 µL per well and exposed to 
PEGylated α-MMC, PEGylated MAP30, and un-PEGylated 
counterparts of 0.012, 0.06, 0.3, and 1.5 mg/mL at 24, 48, 
and 72 hours. Cells without drugs were used as controls. 
Each concentration was tested in quadruplicate. The deter-
mination procedure was carried out according to the previ-
ous description.18 The optical density (OD) at 570 nm was 
measured using an ELISA plate reader (EL × 800, BIO-TEK, 
Atlanta, GA). Cell viability and proliferation were observed 
together with controls.
The inhibitory effect of PEgylated rIPs 
on herpes simplex virus-1
VERO cells were cultured to logarithmic growth phase in 
10 mL DMEM containing 10% (v/v) fetal bovine serum, 
100 µg/mL penicillin, and 100 U/mL  streptomycin. After 
removing medium, cells were substituted to 5 mL of 
the above medium and infected with 100 µL of  herpes 
simplex virus-1 (HSV-1) for 1.5 hours. Then, 5 mL 
maintenance medium containing 2% (v/v) fetal bovine 
serum, 100 µg/mL penicillin, and 100 U/mL streptomycin 
was added and cells were continually cultured for about 
1–2 days when over 80% cells appeared with cytopathic 
effect (CPE). The infected supernatant was collected for 
testing of virus titers.
Determination of virus titer
VERO cells of 1 × 105 cells/mL were applied 100 µL per 
well to 96-well microtiter plates and cultured for 24 hours. 
After discarding medium, 100 µL of infected supernatant, 
which was 10−1 to 10−10 diluted with medium, was added to 
each well (quadruplicate) until CPE did not increase. TCID
50
 
(50 percent tissue culture infective dose) was calculated 
according to Reed and Muench.19,20
Measurement of cytotoxicity
The cytotoxicity of PEGylated α-MMC and PEGylated 
MAP30 was evaluated by the quantitative MTT test.21 
A total of 1 × 105 VERO cells/mL was applied to 96-well 
microtiter plates at 100 µL per well and was exposed 
to un-PEGylated proteins and PEGylated-proteins at 
3.3 µmol ⋅ L−1∼3.3 nmol ⋅ L−1  (100 mg ⋅ L−1∼0.1 mg ⋅ L−1) and 
acyclovir (ACV) at 10 µmol ⋅ L−1∼0.01 µmol ⋅ L−1 for 48 hours 
as well as cells without drugs as control. Each concentration 
was tested in quadruplicate. The determination procedure 
was carried out according to the previous description.18 The 
OD at 490 nm was measured using ELISA:
Cell viability (%)
OD  
OD  
100%
490sample
490sample
 = ×
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Inhibition of proteins on HSV-1 antigen secretion
A total of 1 × 105 VERO cells/mL were seeded into 24-well 
plates at 1 mL/well and then incubated with 5% CO
2
 at 37°C 
for 24 hours. After abandoning the supernatant, 300 µL 
HSV-1 stock solution with 100 TCID
50
/mL was added to each 
well and incubated for 1.5 hours. Then, 100 µL of culture 
medium containing proteins (concentration was mentioned 
previously in the cytotoxity method) was added to each well 
and negative and positive cell control established. After 
incubation for 48 hours, HSV-1 antigen in culture supernatant 
was tested by human HSV-1 antigen 1 (HSV-1 AG1) enzyme-
linked immunosorbent assay kit with indirect ELISA:
The analysis of virus inactivation
VERO cells infected with HSV-1 were added with 20 µL 
(5 mg/mL) of MTT to each well and incubated at 37°C for 
4 hours. Then, 150 µL of DMSO was added to each well. The 
OD
490
 was read by a microplate spectrophotometer. The per-
centage of inhibition was calculated by the formula described 
under the heading “Measurement of cytotoxicity.”
Immunogenicity of PEgylated α-MMC 
and PEgylated MAP30
Fifty Sprague Dawley rats were randomly classified into 
control, α-MMC, PEGylated α-MMC, MAP30, and PEGy-
lated MAP30 groups of ten each. The rats in the control 
group were subcutaneously injected with saline solution, 
and the RIP and PEGylated RIP groups were emulsified in 
Freund’s complete adjuvant at a dose of 1.42 mg/kg at the 
infection frequency of 3 days for 17 days. Blood samples 
were collected from the capillary vessel in rats’ eyes and 
separated sera were stored at –20°C. Antigen-specific serum 
IgG levels were measured by ELISA. Briefly, 96-well plates 
were coated with 100 µL of 30 µg/mL purified antigen 
(RIPs and PEG-RIPs) in 0.05 M carbonate-coating buffer, 
Table 1 Summarization of purification of alpha-momorcharin (α-MMC) and momordica anti-HIV protein (MAP30) from 200 g of bitter 
melon seeds
Steps Total volume (mL) Protein content (mg/mL) Total protein (mg) Field (%)
Extract-free cells 800 15.0 12,000 100
AS precipitation 100 37.5 3750 32.0
SP Sepharose FF 360 2.3 828 6.9
Sephacryl S-100 110 4.5 495 4.1
Macro-Cap-SP α-MMC MAP30 α-MMC MAP30 α-MMC MAP30 α-MMC MAP30
40 35 5.3 3.5 200 120 1.7 1.0
Notes: Values reported are an average value of five preparations. The data from both crude extraction and precipitation with ammonium sulfate were obtained by the 
method of Lowry et al;14 other data were assayed at 280 nm.
1 2 3 4 5 6 7
kDa
66
45
35
27
20
14.4
9.5
6.5
Figure 1 SDS-PAGE of extracts and eluates from different purification steps. Lane 
1: crude extract; Lane 2: dialytic sample after AS precipitation; Lane 3: eluate from 
SP-Sepharose FF chromatography; Lane 4: eluate from gel filtration chromatography; 
Lane 5: α-MMC from Macro-Cap-SP chromatography; Lane 6: MAP30 from Macro-
Cap-SP chromatography; Lane7: LMW calibration kit.
A B
1 2 1 2
Figure 2 Western blot analysis of α-MMC and MAP30. (A) Lane 1: reduced SDS-
PAgE of α-MMC; Lane 2: western blot profile of α-MMC. (B) Lane 1: reduced 
SDS-PAGE of MAP30; Lane 2: western blot profile of MAP30.
Inhibition rate (%)
OD OD
OD
positive control sample
positive con
= −
trol negative controlOD−
× 100%
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pH 9.6, and incubated at 4°C. After washing, 300 µL of 
PBS containing 3% BSA, pH 7.4, was added to each well, 
followed by 2.5 hours of incubation at 37°C. Diluted sera 
(1:16) were added (100 µL/well) and followed by 2.5 hours 
of incubation at 37°C. Wells were then washed in PBS 
washing buffer, pH 7.4, containing 0.05% Tween-20, and 
incubated with peroxidase-conjugated AffiniPure goat 
antimouse IgG (1:16000) at 37°C for 2.5 hours. Then, the 
plate was washed five times in PBS followed by the addition 
of 100 µL/well tetramethyl benzidine ( Sigma-Aldrich) as 
a substrate for horseradish peroxidase. The reactions were 
allowed to develop at 37°C for 15 minutes. Finally, 50 µL 
of 2 M sulfuric acid was added to stop the reaction. The 
absorbance was measured with a plate reader (Model 680, 
Bio-Rad Laboratories) at 450 nm.
Statistical analysis
SPSS statistical software (SPSS, Inc, Chicago, IL) was 
used for analysis. P , 0.05 was considered statistically 
significant.
Results and discussion
Purification and identification  
of α-MMC and MAP30
Purification of α-MMC and MAP30 was performed by apply-
ing 30%–65% ammonium sulfate precipitation, acidification, 
SP-Sepharose FF, Sephacryl S-100, and Macro-Cap-SP 
chromatography. In conclusion, 200 mg of α-MMC and 
120 mg of MAP30 with the recoveries of 1.7% and 1.0%, 
respectively, was obtained from 200 g starting material seeds. 
The procedure of purification is summarized in Table 1. Both 
α-MMC and MAP30 were assessed by SDS-PAGE (Figure 1) 
and Western blotting (Figure 2). By using the Compute pI/
Mw program from ExPASy Proteomics Server (http://www.
expasy.org), the theoretical pI of α-MMC is 9.32 and MAP30 
is 8.86. And this is coincident with the result of IEF analyses 
of these two proteins. ESI-QUAD-MS was used to further 
identify the two proteins, and sequences were analyzed using 
the BLAST program (http://www.expasy.org/tools/blast/), 
which demonstrated that they are α-MMC (Swiss Prot acces-
sion number: P16094, peptides are YLLMHLFNYDGK) and 
MAP30 (Swiss-Prot accession number: P24817, peptides are 
ESPPEAYNILFK). MALDI-TOF-MS was used to determine 
the accurate molecular weight of α-MMC and MAP30. The 
results showed that the molecular weights were 28551.6 Da 
and 29072.0 Da, respectively (Figure 3), while the theoretical 
molecular weight was 27368.36 Da and 29600.74 Da (http://
www.expasy.org). Edman degradation indicated that the 
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Figure 3 MALDI-TOF-MS analyses of both α-MMC and MAP30. (A) MALDI-TOF-MS profile of α-MMC. The average MW of α-MMC was 28551.6 Da (B) MALDI-TOF-MS 
profile of MAP30. The average MW of MAP30 was 29072.0 Da.
1 2 3 4 5 1 2 3 4 5
A B
kDa
170
130
100
70
55
kDa
220
170
110
76
53
40
35
25
15
10
Figure 4 gradient SDS-PAgE of both PEgylated α-MMC and PEgylated MAP30 
conjugates. (A) Lane 1: α-MMC as a control; Lane 2: mixture of α-MMC and α-MMC-
PEG conjugate; Lane 3: purified α-MMC-PEG conjugate; Lane 4: unmodified α-MMC; 
Lane 5: HMW calibration kit. (B) Lane 1: MAP30 as a control; Lane 2: mixture of 
MAP30 and MAP30-PEG conjugate; Lane 3: purified MAP30-PEG conjugate; Lane 4: 
unmodified MAP30; Lane 5: HMW calibration kit.
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N-terminal sequence of the purified proteins, N-Asp-Val-Ser-
Phe-Arg and N-Asp-Val-Asn-Phe-Asp, was consistent with 
theoretical sequences of both α-MMC and MAP30.
Purification and identification  
of PEgylated α-MMC and PEgylated 
MAP30
Through optimized PEGylation reaction, a high total 
PEGylation ratio can be obtained (about 60%–70%). The 
gradient SDS-PAGE monitoring (Figure 4) showed that the 
un-PEGylated counterparts from the reaction mixture were 
successfully removed by Sephacryl S-100 chromatography 
or Superdex 75 chromatography. In the MALDI-TOF-MS 
analysis (Figure 5), one-mer, two-mer, and three-mer PEGy-
lated isomers with 49899.4 Da, 70430.9 Da, and 91057.6 Da 
(the molar ratios of 1:1, 2:1, and 3:1 of (mPEG)
2
-Lys-
NHS:α-MMC) were detected from α-MMC-PEG conjugates. 
Meanwhile, one-mer and two-mer PEGylated isomers with 
50335.6 Da and 70614.2 Da (the molar ratios of 1:1 and 2:1 
of (mPEG)
2
-Lys-NHS: MAP30) were found from MAP30-
PEG conjugates.
Topological inactivation activity
To demonstrate their topological inactivation activity, 
supercoiled DNA (pUC18) was incubated with PEGylated 
RIPs and un-PEGylated counterparts. In suitable enzymatic 
digestion conditions, all of the experiment samples cleaved 
the supercoiled double-stranded DNA to produce nicked 
circular or linear DNA. As shown in Figure 6, all of them 
exhibited DNase-like activity.
Effects of PEgylated α-MMC  
and PEgylated MAP30 on proliferation  
of JAr cells
To investigate the effect of PEGylated α-MMC and PEGy-
lated MAP30 on cell viability and proliferation, JAR cells 
were seeded on 96-well plates and were treated with increas-
ing concentrations of PEGylated RIPs and un-PEGylated 
counterparts for 72 hours (Figure 7A) and for different 
times at 1.5 mg/mL (Figure 7B). Statistical analysis revealed 
that the concentrations of 1.5, 0.3, and 0.06 mg/mL started 
to significantly reduce the proliferation of cells after 
48 and 72 hours of incubation. The analyses with the result 
of Figure 7A exhibited that native α-MMC allowed an 
approximately 21% decrease compared with the PEGylated 
α-MMC and 25% of MAP30 with the PEGylated MAP30 
at the highest tested concentration. This can  indirectly 
demonstrate a dose- and time-dependent inhibition to the 
growth of JAR choriocarcinoma cells. The result in the 
analysis of Figure 7B displayed that the growth of cells was 
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Figure 5 MALDI-TOF-MS analysis of both PEgylated α-MMC and PEGylated MAP30 conjugates. (A) The (mPEG)2-Lys-NHS was around 20 kDa and the PEg conjugates 
were observed at 49899.4 Da, 70430.9 Da and 91057.6 Da, reflecting 1, 2 or 3 PEG-bound chains per α-MMC molecule. (B) The (mPEG)2-Lys-NHS was around 20 kDa and 
the PEG conjugates were observed at 50335.6 Da and 70614.2 Da, reflecting 1 or 2 PEG-bound chains per MAP30 molecule.
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Figure 6 Topological inactivation activities. Lane 1: DNA marker; Lane 2: pUC18 
DNA as a control; Lane 3 and 4: pUC18 DNA was incubated with α-MMC, PEg-α-
MMC; Lane 5 and 6: pUC18 DNA was incubated with MAP30, PEg-MAP30.
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Figure 7 Inhibitory effects of α-MMC/MAP30 and PEg-α-MMC/MAP30 on the proliferation of human choriocarcinoma JAr cells. JAr cells were treated with increasing 
concentrations for 72 hours. (A) and for various time points at 1.5 mg/mL. (B) of native or PEgylated α-MMC/MAP30 as indicated. 
Note: Each data point represents the average of three independent experiments performed in quadruplicate.
not prominent after 24 hours of treatment, but continued 
incubation for 48 or 72 hours with the proteins enhanced the 
cytotoxicity on cells.
α-MMC and PEGylated α-MMC induced alterations in 
the morphology of JAR cells (Figure 8). After processing 
for 72 hours, untreated JAR cells extended and flattened 
(Figure 8A), while the treated groups showed fewer cells 
and abnormal shapes such as shrinkage, blebbing, and 
loss of membrane asymmetry, indicating the cytotoxic 
effect of α-MMC and its modifier on JAR cells. In par-
ticular, α-MMC-treated groups showed extremely obvious 
morphological changes (Figure 8C and D). MAP30 and 
PEGylated MAP30 also showed a similar cytotoxic effect 
to JAR cells.
The inhibitory effect of PEgylated 
α-MMC and PEgylated MAP30 on HSV-1
TCID
50
 was calculated using the method of Reed and 
Muench,19 and the emergence of CPE was used as a posi-
tive sign. The CPE of each dilution of HSV-1 cytopathic 
was tabulated as in Table 2. Measurement of cytotoxicity 
was designed to establish appropriate dose range for the 
research of inhibitory effect of proteins on HSV-1 to VERO 
cells. The result (Figure 9) reflected the effects of different 
concentrations of test proteins on cell viability of VERO cells 
and showed that α-MMC/MAP30, PEG-α-MMC/MAP30, 
and ACV had no significant inhibition on VERO cells in the 
tested concentration range. The cell viability maintained 
above 97% from 0.003–0.03 µmol ⋅ L−1 and 85% from 0.3–3.3 
Figure 8 Morphological differences in JAR cells for 72 hours culture photographed by phase contrast microscopy. JAR cells treated without drugs (A), with 15 μg/mL 
5-fluorouracil (B), with 0.3 (C) and 1.5 mg/mL α-MMC (D) and with 0.3 (E) and 1.5 mg/mL PEg-α-MMC. (F) The white bar presents 50 μm.
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Table 2 Herpes simplex virus-1-induced cytopathic effect (CPE) 
of VERO cell (50% tissue culture infective dose (TCID50) = antilog 
[(55.6–50)/55.6–20) × (−1) + (lg10–5)] = 10–5.2/0.1 mL = 10–6.2/mL)
Virus  
ratio  
dilution
CPE appearing  
in cell holes
Total 
number  
of cell holes
CPE  
appearing in 
cell holes (%)Positive Negative
−3 16 0 16 100
−4 10 1 11 90.9
−5 5 4 9 55.6
−6 2 8 10 20
−7 0 14 14 0
–8 0 20 20 0
70
0
0
Proteins
ACV
0.003
0.01
0.03
0.1
0.3
1
3.3
10
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75
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Figure 9 Different concentrations of proteins on cell viability of VErO cells.
Abbreviations: α-MMC, alpha-momorcharin; MAP30, momordica anti-HIV protein; 
PEg, polyethylene glycol; ACV, acyclovir.
µmol ⋅ L−1. Therefore, the dose range of tested proteins inhibit-
ing VERO cell infection with virus was below 3.3 µmol ⋅ L−1. 
The inhibitory effect of α-MMC/MAP30, PEGylated 
α-MMC/MAP30, and ACV on HSV-1 glycoprotein antigen 
 secretion glycoprotein was tested through the determination 
of HSV-1 glycoprotein antigen (Table 3). The results showed a 
dose-dependent inhibitory effect. IC
50
 was 0.67 µmol ⋅ L−1 with 
α-MMC, 2.94 µmol ⋅ L−1 with PEG-α-MMC, 0.47 µmol ⋅ L−1 
with MAP30, 2.39 µmol ⋅ L−1 with PEG-MAP30, and 
3.55 µmol ⋅ L−1 with ACV, respectively.  Furthermore, 
IC
50
 of α-MMC/MAP30 and PEG-α-MMC/MAP30 was 
lower than the general drug of ACV. At the same dose, the 
inhibitory effect on HSV-1 glycoprotein antigen secretion, 
glycoprotein of MAP30 was higher than that of α-MMC 
and PEG-MAP30 was higher than PEG-α-MMC. The MTT 
results showed that the ratio of cell viability can be increased 
on a dose-dependent feature compared with the control group 
when protein concentration was higher than 0.03 µmol ⋅ L-1. 
But ACV did not display effects on HSV-1 inactivation. At 
the same dose, the ratio of cell viability with MAP30 was 
higher than α-MMC and PEG-MAP30 was higher than 
PEG-α-MMC. This indicated that both α-MMC/MAP30 and 
PEG-α-MMC/MAP30 had the ability of direct HSV-1 inac-
tivation in a certain range of concentration. Additionally, 
the effect of inactivation was obvious with the increase of 
Table 3 Inhibitory effects of RIPs and PEGylated RIPs on herpes simplex virus-1 (HSV-1) antigen
Protein Concentration OD450 of HSV-1  
antigen
Inhibition ratio of  
HSV-1 antigen (%)
50% inhibiting  
concentration (μmol-1)
Positive control 
Negative control
µmol ⋅ L−1,* 0.923 ± 0.008 
0.004 ± 0.001
0
α-MMC 3.3 
0.3 
0.03 
0.003
0.270 ± 0.011 
0.550 ± 0.009 
0.827 ± 0.003 
0.892 ± 0.004
71.055 
40.588 
10.446 
3.373
0.67
α-MMC-PEg 3.3 
0.3 
0.03 
0.003
0.452 ± 0.004 
0.689 ± 0.004 
0.866 ± 0.004 
0.902 ± 0.003
51.270 
25.508 
6.241 
2.250
2.94
MAP30 3.3 
0.3 
0.03 
0.003
0.220 ± 0.002 
0.507 ± 0.010 
0.807 ± 0.006 
0.890 ± 0.001
76.488 
45.320 
12.591 
3.556
0.47
MAP30-PEg 3.3 
0.3 
0.03 
0.003
0.429 ± 0.003 
0.674 ± 0.004 
0.854 ± 0.003 
0.902 ± 0.000
53.740 
27.105 
7.5472 
2.286
1.17
Acyclovir 10 
1 
0.1 
0.01
0.354 ± 0.004 
0.597 ± 0.006 
0.872 ± 0.003 
0.921 ± 0.006
61.901 
35.450 
5.515 
0.254
2.39
Note: *Compared with positive control P , 0.01.
Abbreviations: α-MMC, alpha-momorcharin; MAP30, momordica anti-HIV protein; PEg, polyethylene glycol.
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protein concentration. VERO cells infected with HSV-1 after 
48 hours displayed alterations in the morphology. The inhibi-
tory effect can be observed in groups of α-MMC/MAP30, 
PEG-α-MMC/MAP30, and ACV (Figure 10). The extent of 
cytopathy was gradually reduced with the increase of the 
protein concentration. In groups of α-MMC and MAP30, 
most cells did not appear cytopathic caused by virus at a 
concentration of 3.3 µmol ⋅ L−1. This indicated that proteins 
played an important role in the inhibition on HSV-1.
Evaluation of immunogenicity of both 
PEgylated MAP30 and PEgylated 
α-MMC in Sprague Dawley rats
The antigenicity of native and two PEGylated RIPs was 
evaluated by measuring the specific IgG antibody titers of 
the serum of Sprague Dasley rats. The results showed that the 
PEGylated RIPs allowed to some extent decrease of immu-
nogenicity while compared with un-PEGylated counterparts. 
The decrease of IgG generation was approximately 70% 
for PEGylated α-MMC compared with the un-PEGylated 
counterpart and 50% for PEGylated MAP30 compared with 
the un-PEGylated counterpart.
Conclusion
A novel preparative strategy of both α-MMC and MAP30 
at one time was successfully established. Some  properties of 
these proteins were assessed by SDS-PAGE, ESI-QUAD-MS, 
MALDI-TOF-MS, and N-terminal sequence as well as 
 Western blotting. This fast, highly efficient methodology 
enables us to focus more energy on subsequent research. 
A branched (mPEG)
2
-Lys-NHS(20 kDa) was used to modify 
these proteins and the serial PEGylated ones were assessed 
by gradient SDS-PAGE and MALDI-TOF-MS. The α-MMC 
modifier possessed one-mer, two-mer, and three-mer PEG-
bound chains, while MAP30 modifier obtained one-mer 
and two-mer PEG-bound chains. PEGylated conjugates 
preserved moderate activities on JAR choriocarcinoma cells 
and HSV-1. Furthermore, both PEGylated proteins showed 
about 60%–70% antitumor and antivirus activities as well 
as a 50%–70% immunogenicity decrease when compared 
with unmodified counterparts. To sum up, PEGylation of 
α-MMC and MAP30 may offer a possible way for their clini-
cal application as potential therapeutic agents. Nevertheless, 
to fulfill the requirements of a useful drug, we should meet 
the challenges, including the reduction of immunogenicity 
to the greatest extent, the retention of sufficient activity, the 
extension of the half-life period, and development of vari-
ous forms of PEG-RIPs. This work is just the beginning for 
them to be used clinically. After all, therapeutic proteins must 
fulfill the requirements described previously. PEGylation can 
reduce immunogenicity and retain certain biological activity 
of RIPs, but there is lots of work to do for further decreas-
ing their immunogenicity and extending the half-life period. 
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Figure 10 The ratio of cell viability under different concentration of proteins.
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Future work concerns packing RIPs with nanomaterials for 
targeting drugs and low release.
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